MMJ Files Application With FDA to Begin Clinical Trial of Cannabis-Based Meds to Treat Huntington’s

MMJ International has filed two applications with the U.S. Food and Drug Administration (FDA) requesting permission to begin clinical studies to test its pharmaceutical grade cannabis-based therapies in easing symptoms associated with Huntington’s disease and multiple sclerosis.

MMJ also has requested a meeting with FDA officials to discuss the development process for an investigational new drug (IND). A pre-IND meeting helps create a strategy for the drug development process by reviewing the clinical trial design, sharing ideas, and understanding the specific expectations and requirements for a future IND application. This step, in turn, may shorten the time necessary to bring the product to market.

“The filing of these applications with the FDA brings us one step closer to helping persons suffering from these debilitating diseases. As a company, we are committed to researching and developing cannabis based medicines which will improve the lives of people around the world,” said Duane Boise, CEO

... read more at: